"Tissue" or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca(2+)-dependent post-translational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntington's (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.

Malorni, W., Farrace, M.g., Rodolfo, C., Piacentini, M. (2008). Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection. CURRENT PHARMACEUTICAL DESIGN, 14(3), 278-288 [10.2174/138161208783413220].

Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection

FARRACE, MARIA GRAZIA;RODOLFO, CARLO;PIACENTINI, MAURO
2008-01-01

Abstract

"Tissue" or type 2 Transglutaminase (TG2) is a peculiar multifunctional enzyme able to catalyse Ca(2+)-dependent post-translational modification of proteins, by establishing covalent bonds between peptide-bound glutamine residues and either lysine residues or mono- and poly-amines. In addition, it may act also as a G protein in transmembrane signalling, as a kinase, as a protein disulphide isomerase and as a cell surface adhesion mediator. The vast array of biochemical functions exerted by TG2 characterises and distinguishes it from all the other members of the transglutaminase family. Multiple lines of evidence suggest an involvement of the enzyme in neurodegenerative diseases, such as Huntington's (HD) and Parkinson (PD), and that its inhibition, either via drug treatments or genetic approaches, might be beneficial for the treatment of these syndromes. This review will exploit the recent developments in the comprehension of the role played by type 2 transglutaminase in eukaryotic cells, focusing on the role exerted by TG2 on mitochondrial physiology and on the regulation of cell death pathways at the basis of neurodegenerative diseases.
2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore BIO/06 - ANATOMIA COMPARATA E CITOLOGIA
English
Con Impact Factor ISI
Transglutaminases; Cell Survival; Neurodegenerative Diseases; Autophagy; GTP-Binding Proteins; Cell Death; Animals; Eukaryotic Cells; Drug Delivery Systems; Mitochondria; Humans; Gene Expression Regulation, Enzymologic
Malorni, W., Farrace, M.g., Rodolfo, C., Piacentini, M. (2008). Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection. CURRENT PHARMACEUTICAL DESIGN, 14(3), 278-288 [10.2174/138161208783413220].
Malorni, W; Farrace, Mg; Rodolfo, C; Piacentini, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/19320
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 30
social impact